Last reviewed · How we verify

Mifepristone plus two doses Misoprostol

Planned Parenthood League of Massachusetts · Phase 3 active Small molecule

Mifepristone blocks progesterone receptors to halt pregnancy, followed by misoprostol doses that induce uterine contractions to expel pregnancy tissue.

Mifepristone blocks progesterone receptors to halt pregnancy, followed by misoprostol doses that induce uterine contractions to expel pregnancy tissue. Used for Medical abortion in early pregnancy (up to 10 weeks gestation).

At a glance

Generic nameMifepristone plus two doses Misoprostol
SponsorPlanned Parenthood League of Massachusetts
Drug classProgesterone receptor antagonist + prostaglandin analog combination
TargetProgesterone receptor (PR); prostaglandin E1 receptor (EP receptor)
ModalitySmall molecule
Therapeutic areaReproductive Health / Obstetrics
PhasePhase 3

Mechanism of action

Mifepristone is a selective progesterone receptor antagonist that terminates early pregnancy by blocking progesterone's effects on the uterus, causing decidualization reversal and detachment of the conceptus. Misoprostol, a prostaglandin analog, is then administered in two doses to stimulate uterine contractions and facilitate expulsion of pregnancy tissue through the cervix.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: